NEW YORK — Tempus said on Friday that it has struck a multiyear deal to provide its next-generation sequencing-based cancer tests to the US Department of Veterans Affairs (VA) National Precision Oncology Program (NPOP).
Under the terms of the deal, NPOP healthcare providers at the VA's 171 medical centers can access the tests including Tempus' solid tumor/normal and liquid biopsy assays. In the event of insufficient tumor tissue, Chicago-based Tempus said it offers a conversion option to a blood-based liquid biopsy test.
Financial and other terms were not disclosed.
"Our AI-enabled tests combine high-quality and comprehensive genomic data with clinical data for each patient being sequenced, which allows physicians to make truly personalized decisions as they seek the optimal therapy for their patients," Tempus Founder and CEO Eric Lefkofsky said in a statement. "We look forward to supporting the VA as they expand access to precision medicine solutions in oncology care."